Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit ⊕
Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of tariffs."
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.